Sage Journals: Discover world-class research

Abstract

Background:

Haematological toxicities (anaemia, neutropenia and thrombocytopenia), a known class effect of poly-ADP ribose polymerase inhibitors (PARPi) may limit exposure to PARPi and therefore impact efficacy.

Objective:

This study aimed to provide practical and detailed recommendations for the prevention and management of these toxicities in metastatic prostate cancer in the real world.

Design:

A national consensus study was performed using a modified Delphi methodology.

Methods:

A multidisciplinary steering committee of 9 French experts formulated and submitted 38 statements to the vote of 33 French healthcare professionals experienced in oncology and PARPi in prostate and/or breast/ovarian cancers.

Results:

All recommendations achieved a consensus. Before initiating PARPi, haematological disorders should be investigated and appropriate corrective measures implemented. The haemoglobin level should ideally be ⩾10 g/dl and a minimum delay of 4 weeks should be respected after chemotherapy. Monitoring should be frequent for the first 3 months of treatment, at least every 15 days, and even more frequent in patients at high-risk of toxicity. In the event of symptomatic grade 2 or 3 anaemia, grade 2 or 3 thrombocytopenia and grade 3 neutropenia, PARPi treatment should be discontinued until return to grade 1. Transfusion may be considered in symptomatic grade 2 or 3 anaemia. Myelodysplastic syndrome/acute myeloid leukaemia should be suspected in cases of cytopenia persisting beyond 4 weeks or changes in the blood count after maintenance of an optimal therapeutic dose over the long term.

Conclusion:

These proposals complement existing recommendations to guide healthcare professionals in real-world practice, and so optimise metastatic prostate cancer patient’s ability to maximally benefit from PARPi.

Keywords

DELPHI consensus haematological toxicities PARP inhibitor prostate cancer toxicity management

Introduction

In Europe, prostate cancer accounts for 20% of male cancers and is the third leading cause of cancer deaths in men.¹ While most prostate cancers are diagnosed at a very early stage and can be successfully managed by active surveillance, radical prostatectomy or radiotherapy, some will progress to metastatic, hormone-sensitive or castration-resistant prostate cancer (mCRPC), associated with an unfavourable prognosis.² The recent development of new therapies and precision medicine supports improved control of tumour progression and improved survival in advanced metastatic cancer patients.³ These advances include poly-ADP ribose polymerase inhibitors (PARPi) – PARP being a family of proteins involved in the repair of DNA single-strand breaks by homologous recombination.^3,4

Initially developed for breast/ovarian cancers, PARPi are now used in mCRPC as monotherapy or in combination with androgen receptor pathway inhibitors (ARPI), including abiraterone and enzalutamide.^5,6 Indeed, two phase III studies have demonstrated a significant benefit in radiographic progression-free survival (rPFS) for rucaparib, and in overall survival (OS) for olaparib as monotherapy in patients with alterations in homologous recombination repair (HRR) genes. Moreover, in combination, two phase III studies have shown a benefit in rPFS (olaparib + abiraterone plus corticosteroids), and in OS (talazoparib + enzalutamide) in mCRPC patients in the general population, and one phase III study demonstrated a benefit in rPFS in HRR populations (niraparib + abiraterone plus corticosteroids).^7
–12 These promising data led to approvals for olaparib, niraparib, rucaparib and talazoparib, either as monotherapy or in combination with ARPI, in patients with mCRPC with or without alterations in HRR genes, depending on the country.^13
–16

Experience with PARPi in other cancers has demonstrated a relationship between exposure and efficacy, confirmed in mCRPC, underlining the importance of maintaining an optimal dosage.^17
–19 However, the phase III studies have shown that PARPi induce haematological adverse effects, mainly anaemia (grade ⩾3: 16.3%–46.0%), neutropenia (grade ⩾3: 5.0%–18.0%) and thrombocytopenia (grade ⩾3: 0.3%–7.0%), which frequently lead to dose adjustment, interruption or discontinuation of treatment.^7
–9,11,12 These observations have been supported by systematic reviews and meta-analyses confirming a class effect of PARPi.^20
–22 It is therefore crucial to define appropriate monitoring and management to prevent unnecessary dose reductions, temporary or permanent discontinuations and unnecessary blood transfusions. However, in the Summaries of Product Characteristics (SmPCs) of the available PARPi and in published recommendations, the management of these haematological toxicities is not always detailed, particularly regarding prevention, nor is it specific to prostate cancer.^{13
–15,23
–25}

In this context, a multidisciplinary group of French experts in prostate cancer and/or treatment with PARPi used a modified Delphi methodology to define more precise and standardised practical recommendations to help healthcare professionals (HCPs) better prevent and manage PARPi-associated haematological toxicities in patients with mCRPC in real-life practice to support treatment continuation.

Methodology

The Delphi method is a formalised consensus approach by an iterative multi-step process.^26,27 Commonly used in healthcare, including oncology, it is based on four principles: anonymity, iteration, controlled feedback and statistical aggregation of responses.^28,29 The key steps include the drafting of statements by a steering committee (SC), anonymous and iterative scoring by a panel of experts (voting group), feedback based on previous responses and finalisation of recommendations.^27,28 Our modified Delphi-type national consensus, in line with French and international recommendations, took place from July to November 2024.

The SC, comprising nine experts (five medical oncologists, one onco-haematologist, one urologist, one pharmacist and one advanced practice nurse) with a strong commitment to, and experience in, prostate cancer and/or PARPi use, formulated statements on the prevention and management of haematological toxicities associated with PARPi in the treatment of mCRPC based on the literature and their practical experience.

These statements were submitted to the vote of experts selected according to several criteria: speciality (oncologists, onco-haematologists, urologists, haematologists), with strong expertise in oncology and experience in PARPi use in prostate or breast/ovarian cancers. HCPs from across France were invited to participate to ensure representativity.

In accordance with the HAS (French health authority) recommendations, the experts expressed their level of agreement with each statement via an online questionnaire, using a nine-point Likert scale, ranging from 1 (‘Strongly disagree’) to 9 (‘Strongly agree’). In the first round only, experts could explain their vote with a comment. A STRONG consensus was reached if more than 75% of the votes were ⩾7 and the median ⩾8. If only one of these criteria was met, the statement achieved a GOOD consensus. The process involved two voting rounds. After the first voting round, the SC reviewed the results and comments (Figure 1).

- Proposals that reached a consensus within the group were retained;

- those where divergences had been identified were revised based on the experts’ comments and submitted to a second voting round.

The participants remained anonymous throughout the process and had no interaction with the SC, whose members did not take part in the vote in accordance with the methodological recommendations in force.²⁸

Figure 1.

Delphi study methodology.

All personal data collected as part of this programme were dissociated from the results and anonymised, in accordance with French data protection law (General Data Protection Regulation).

Results

Characteristics of respondents

A total of 33 HCPs took part in the consensus, including 25 medical oncologists, 5 urologists, 1 haematologist, 1 general practitioner working in a cancer centre and 1 radiation oncologist. Their profiles are detailed in Table 1.

Table 1.

Characteristics of voting experts.

Speciality (n (%)), n = 33
Medical oncologist	25 (76)
Urologist^a	5 (15)
Haematologist	1 (3)
Other^b	2 (6)
Gender (n (%)), n = 33
Female	11 (33)
Male	22 (67)
Age (median (Q1–Q3), years), n = 33	43 (37–48)
Experience (median Q1–Q3), years), n = 33	11 (7–18)
Main type of practice (n(%)), n = 33
Hospital	30 (91)
Self-employed	2 (6)
Mixed	1 (3)
Region of practice (n(%)), n = 33
Paris/Île-de-France	9 (27)
Auvergne-Rhône-Alpes	5 (15)
New Aquitaine	4 (12)
Burgundy-Franche-Comté	3 (9)
Occitania	3 (9)
Great East	2 (6)
Brittany	1 (3)
Corsica	1 (3)
Hauts-de-France	1 (3)
Pays de la Loire	1 (3)
Provence-Alpes-Côte d’Azur	1 (3)
Normandy	1 (3)
DROM-COM	1 (4)
Type of patients treated (n(%)), n = 33
Metastatic prostate cancer only	21 (64)
Breast/ovarian cancers only	2 (6)
Both	8 (24)
Not applicable	2 (6)
Number of patients treated with PARPi/year (median (Q1–Q3))
Metastatic prostate cancer, n = 29	5 (2–10)
Breast/ovarian cancers, n = 9	10 (5–15)
Oncology management activities with PARPi in the last 5 years (n(%)), n = 28
Participation in a clinical trial/research project on PARPi (outside this project)	25 (89)
Participating as a speaker/trainer at scientific days on PARPi topics	16 (57)
Author of a conference abstract/scientific article on PARPi	14 (50)
Participation in a working group on oncology management with PARPi	14 (50)

^aFour urologists reported treating between 2 and 15 metastatic prostate cancer patients per year with PARPi. One urologist was a member of a working group focused on oncology management involving PARPi, and participated as a speaker/trainer at scientific events dedicated to PARPi-related topics.

^bOne general practitioner working in a cancer centre and 1 radiation oncologist treating 8 metastatic prostate cancer patient per year.

PARPi, poly-ADP ribose polymerase inhibitors.

Voting experts had a median age of 43 years (Q1 = 37, Q3 = 48) and had been practising for a median of 11 years (Q1 = 7, Q3 = 18), mostly in hospitals (91%). Nearly two-thirds (64%) had expertise in prostate cancer alone, 6% in breast/ovarian cancers alone, and 24% in both.

In addition to their clinical experience, 85% of voting experts also reported activities related to oncology management with PARPi, such as participating in clinical trials, research projects, working groups or scientific events as speakers or trainers, and authoring abstracts or publications.

Statements

Voting experts were invited to give their opinion on 38 statements formulated by the SC. Ten of these concerned the prevention of haematological toxicities associated with PARPi, with recommendations for initiation (pre-therapy assessment, what to do in the event of pre-existing haematological abnormalities or specific situations such as previous chemotherapy or moderate-to-severe renal failure); frequency and modalities of haematological monitoring, prophylactic measures and multidisciplinary coordination of care (Table 2). Twenty-seven statements concerned the management of haematological toxicities: biological assessment and action to be taken (Tables 3 and 4):

- grade 2 anaemia (haemoglobin 8–10 g/dl): 6 statements

- grade 3 anaemia (haemoglobin <8 g/dl): 7 statements

- grade 2 neutropenia (1000–1500 ANC/µl): 3 statements

- grade 3 neutropenia (<1000 ANC/µl): 5 statements

grade 2 thrombocytopenia (50,000–75,000 platelets/µl): 3 statements

- grade 3 thrombocytopenia (<50,000 platelets/µl): 3 statements.

The last statement addressed situations that should suggest a risk of myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML; Table 4).

Table 2.

Statements relating to the prevention of haematological toxicities with PARPi treatment in prostate cancer.

Statements		Votes (n)	Values1-2-3% (n)	Values4-5-6% (n)	Values7-8-9% (n)	Median	Consensus
1	As part of the prevention of haematological toxicities mediated by PARPi alone or in combination with new-generation hormone therapy (ARPI) in patients with prostate cancer, a biological assessment including blood count, serum creatinine, iron status, vitamin B9 concentration (folic acid), in addition to the other biological parameters conventionally measured, should be systematically carried out.	33	12 (4)	6 (2)	82 (27)	8	STRONG
2	If anaemia is detected during the pre-treatment biological assessment, a possible vitamin B12 deficiency should be investigated.	33	0 (0)	15 (5)	85 (28)	8	STRONG
3	Prophylactic treatment (EPO, G-CSF, iron or vitamin B12 or folic acid supplementation, blood transfusion, antibiotics) is not recommended when initiating treatment with PARPi, in the absence of data demonstrating its benefit.	33	18 (6)	6 (2)	76 (25)	9	STRONG
4	In patients with pre-existing anaemia, treatment with PARPi may be initiated concomitantly with correction of the anaemia, ideally targeting a rate ⩾10 g/dl. Close monitoring is required.	33	3 (1)	12 (4)	85 (28)	7	GOOD
5	In patients with a deficiency in iron, vitamin B9 (folic acid) or vitamin B12, appropriate supplementation should be prescribed.	33	0 (0)	3 (1)	97 (32)	9	STRONG
6	In the event of prior chemotherapy, initiation of PARPi treatment should be deferred, if possible for at least 4 weeks, after the last course of treatment, provided that haematological recovery is sufficient (haemoglobin ⩾10 g/dl; NN >1500/µl; platelets >100,000/µl).	32	6 (2)	13 (4)	81 (26)	8	STRONG
7	Once treatment with PARPi has been initiated, haematological monitoring by haemogram should be carried out, at least every 15 days for the first 3 months (to be adapted according to the recommendations of the PARPi SmPC and the initial haemogram), then every month if clinically justified.	33	6 (2)	6 (2)	88 (29)	8	STRONG
8	In certain patient profiles, blood counts may need to be monitored more frequently after the first month: – Elderly and/or frail patients – Post-CT or radiotherapy anaemia – Heart/liver/kidney failure.	33	0 (0)	3 (1)	97 (32)	8	STRONG
9	In patients with moderate-to-severe renal impairment, a reduced dose of PARPi should be considered from the start of treatment (in accordance with the recommendations in the PARPi SmPC).	33	6 (2)	18 (6)	76 (25)	7	GOOD
10	When PARPi is initiated, it is advisable to carry out a drug conciliation (hospital or community pharmacist), and if the centre’s organisation allows, a tripartite consultation (oncologist, RN/APN and pharmacist).	33	0 (0)	6 (2)	94 (31)	9	STRONG

APN, advanced practice nurse; EPO, erythropoietin; G-CSF, granulocyte colony-stimulating factor; PARPi, poly-ADP ribose polymerase inhibitors; RN, Registered Nurse; SmPC, summaries of product characteristics.

Table 3.

Statements relating to the management of anaemia associated with PARPi treatment in prostate cancer.

Statements		Votes (n)	Values1-2-3% (n)	Values4-5-6% (n)	Values7-8-9% (n)	Median	Consensus
GRADE 2 anaemia (haemoglobin 8–10 g/dl)
11	In the event of a first occurrence of grade 2 anaemia (haemoglobin 8–10 g/dl), a full biological assessment should be carried out, including a haemogram, a vitamin B9 ± B12 panel and an iron status to determine the underlying cause of the anaemia.	33	0 (0)	0 (0)	100 (33)	9	STRONG
12	In the case of symptomatic grade 2 anaemia (haemoglobin 8–10 g/dl) attributable to PARPi, it is recommended that PARPi treatment be withheld until the anaemia returns to grade 1 (haemoglobin ⩾10 g/dl), and that PARPi be restarted at the next lower dose. If the anaemia is not due to PARPi, PARPi can be restarted at the same dose.	32	6 (2)	19 (6)	75 (24)	8	STRONG
13	In the event of the first occurrence of grade 2 anaemia (haemoglobin 8–10 g/dl), weekly haemogram monitoring should be carried out until the anaemia returns to grade 1 (haemoglobin ⩾10 g/dl).	33	15 (5)	15 (5)	70 (23)	8	STRONG
14	In the case of symptomatic grade 2 anaemia (haemoglobin 8–10 g/dl), a transfusion may be considered, depending on the intensity of the symptoms, the speed of onset, co-morbidities, particularly cardiac, and any deficiencies to be corrected. NB: The transfusion threshold may vary according to the patient’s comorbidities. Refer to transfusion recommendations.	33	0 (0)	12 (4)	88 (29)	8	STRONG
15	In the event of a first occurrence of grade 2 anaemia (haemoglobin 8–10 g/dl), the iron and/or vitamin deficiencies revealed by the tests should be corrected by supplementation with iron and/or vitamins B9/12.	33	9 (3)	18 (6)	73 (24)	9	STRONG
16	In the event of a first grade 2 anaemia event (haemoglobin 8–10 g/dl), the prescription of EPO is not recommended, except in patients with chronic renal failure. NB: Refer to the recommendations for prescribing EPO.	33	0 (0)	18 (6)	82 (27)	8	STRONG
GRADE 3 anaemia (haemoglobin <8 g/dl)
17	In the event of a first occurrence of grade 3 anaemia (haemoglobin <8 g/dl), a complete biological assessment including a haemogram, an iron status and an evaluation of vitamin B9 (folic acid) levels should be carried out in order to determine the underlying cause of the anaemia.	33	3 (1)	12 (4)	85 (28)	9	STRONG
18	In the case of grade 3 anaemia (haemoglobin <8 g/dl), it is recommended that PARPi treatment be suspended until the anaemia returns to grade 1 (haemoglobin ⩾10 g/dl), then PARPi should be restarted at the next lower dose.	33	3 (1)	9 (3)	88 (29)	8	STRONG
19	In the event of the first occurrence of grade 3 anaemia (haemoglobin <8 g/dl), weekly haemogram monitoring should be carried out until the anaemia returns to grade 1 (haemoglobin ⩾10 g/dl).	33	0 (0)	12 (4)	88 (29)	8	STRONG
20	In the case of grade 3 anaemia (haemoglobin <8 g/dl), management includes transfusion to achieve, ideally, a haemoglobin rate ⩾10 g/dl. NB: The transfusion threshold may vary according to the patient’s comorbidities. Refer to transfusion recommendations	33	0 (0)	3(1)	97 (32)	8	STRONG
21	In the event of a first occurrence of grade 3 anaemia (haemoglobin <8 g/dl), the iron/vitamin deficiencies revealed by the tests should be corrected by supplementation with iron and/or vitamins B9/12.	33	3 (1)	3 (1)	94 (31)	9	STRONG
22	In the event of a first grade 3 anaemia event (haemoglobin <8 g/dl), the prescription of EPO is not recommended, except in patients with chronic renal failure. NB: Refer to the recommendations for prescribing EPO.	33	9 (3)	15 (5)	76 (25)	8	STRONG
23	If grade 3 anaemia (haemoglobin <8 g/dl) persists or recurs beyond 4 weeks after holding of PARPi therapy and a transfusion, a myelogram (cytological, cytogenetic and molecular analysis) should be performed to investigate the underlying cause.	33	3 (1)	18 (6)	79 (26)	9	STRONG

EPO, erythropoietin; PARPi, poly-ADP ribose polymerase inhibitors.

Table 4.

Statements relating to the management of neutropenia and thrombocytopenia associated with PARPi treatment in prostate cancer and risk of MDS/AML.

Statements		Votes (n)	Values1-2-3% (n)	Values4-5-6% (n)	Values7-8-9% (n)	Median	Consensus
Grade 2 neutropenia (1000–1500 ANC/µl)
24	If fever develops (oral temperature ⩾38.5°C on one occasion or ⩾38°C for at least 1 h), a blood count should be performed to check for neutropenia.	33	0 (0)	12 (4)	88 (29)	9	STRONG
25	In the event of the first occurrence of grade 2 neutropenia (1000–1500 ANC/µl), it is recommended that treatment be continued at the same dose, with blood count monitoring every 1–2 weeks, until grade 1 neutropenia returns (⩾1500 ANC/µl).	33	6 (2)	15 (5)	79 (26)	8	STRONG
26	It is essential to tell patients and carers to seek medical attention immediately in the event of fever (oral temperature ⩾38.5°C on one occasion or ⩾38°C for at least 1 h) and/or chills.	33	0 (0)	12 (4)	88 (29)	9	STRONG
Grade 3 neutropenia (<1000 ANC/µl)
27	In the event of a first occurrence of grade 3 neutropenia (<1000 ANC/µl), it is recommended that PARPi be withheld until grade 1 neutropenia (⩾1500 ANC/µl) is restored, and that treatment be resumed at the next lower dose.	33	0 (0)	15 (5)	85 (28)	8	STRONG
28	In the event of the first occurrence of grade 3 neutropenia (<1000 ANC/µl), weekly blood count monitoring should be carried out until grade 1 neutropenia (⩾1500 ANC/µl) is restored.	33	3 (1)	9 (3)	88 (29)	9	STRONG
29	If grade 3 neutropenia (<1000 ANC/µl) persists or recurs beyond 4 weeks after holding of PARPi therapy, a myelogram (cytological, cytogenetic and molecular analysis) should be performed to investigate the underlying cause.	33	6 (2)	9 (3)	85 (28)	9	STRONG
30	It is essential to tell patients and carers to seek medical attention immediately in the event of fever (oral temperature ⩾38.5°C on one occasion or ⩾38°C for at least 1 h) and/or chills.	33	0 (0)	12 (4)	88 (29)	9	STRONG
31	The combined use of G-CSF and PARPi is not recommended for the prevention or correction of febrile neutropenia.	33	3 (1)	9 (3)	88 (29)	9	STRONG
Grade 2 thrombocytopenia (50,000–75,000 platelets/µl)
32	In the event of a first occurrence of grade 2 thrombocytopenia (50,000–75,000 platelets/µl), it is recommended that PARPi should be suspended until the level returns to ⩾100,000 platelets/µl, and then treatment should be resumed at the next lower dose.	33	3 (1)	15 (5)	82 (27)	9	STRONG
33	In the event of a first occurrence of grade 2 thrombocytopenia (50,000–75,000 platelets/µl), blood counts should be monitored at least once a week until the level returns to ⩾100,000 platelets/µl, depending on the kinetics of platelet decline and the patient’s co-morbidities.	33	3 (1)	6 (2)	91 (30)	9	STRONG
34	If grade 2 thrombocytopenia (50,000–75,000 platelets/µl) persists or recurs beyond 4 weeks after holding of PARPi therapy, a myelogram (cytological, cytogenetic and molecular analysis) should be carried out to investigate the underlying cause.	33	3 (1)	12 (4)	85 (28)	9	STRONG
Grade 3 thrombocytopenia (<50,000 platelets/µl)
35	In the event of a first occurrence of grade 3 thrombocytopenia (<50,000 platelets/µl), it is recommended that PARPi be withheld until the level returns to ⩾100,000 platelets/µl, and then treatment should be resumed at the next lower dose.	33	0 (0)	3 (1)	97 (32)	9	STRONG
36	In the event of a first occurrence of grade 3 thrombocytopenia (<50,000 platelets/µl), twice weekly monitoring by haemogram is recommended until a level ⩾100,000 platelets/µl is reached.	33	6 (2)	9 (3)	85 (28)	8	STRONG
37	If grade 3 thrombocytopenia (<50,000 platelets/µl) persists or recurs more than 4 weeks after holding of PARPi therapy, a myelogram (cytological, cytogenetic and molecular analysis) should be performed to investigate the underlying cause.	33	3 (1)	6 (2)	91 (30)	9	STRONG
Risk of MDS/AML
38	The following situations should lead to the suspicion of MDS/AML, necessitating a haematological opinion for a myelogram (cytogenetic and molecular analysis): – cytopenia persisting beyond 4 weeks despite therapeutic adjustment or holding of PARPi therapy – changes in the blood count after maintenance of an optimal therapeutic dose over the long term	33	0 (0)	18 (6)	82 (27)	8	STRONG

AML, acute myeloid leukaemia; G-CSF, granulocyte colony-stimulating factor; MDS, myelodysplastic syndrome; PARPi, poly-ADP ribose polymerase inhibitors.

From the first voting round, 30 statements achieved a STRONG consensus (⩾75% of votes ⩾7 and median ⩾8), 3 achieved a GOOD consensus (⩾75% of votes ⩾7 or median ⩾8) and 5 did not reach consensus. Based on the experts’ comments, seven statements – two with a GOOD consensus and five without consensus – were revised by the SC for a second voting round.

After this second round, 6/7 statements achieved a STRONG consensus, and 1/7 received a GOOD consensus.

In total, after two voting rounds, a consensus was reached for all the proposals. The distribution of votes, medians and results is shown in Tables 2 –4.

Discussion

Prescription of PARPi requires particular attention to haematological toxicities, a known class effect which can lead to dose reductions or frequent treatment interruption and discontinuation. Using a modified Delphi methodology, this research has resulted in 38 practical and detailed recommendations (achieving 100% consensus among experts) to help HCPs prevent and manage anaemia, neutropenia and thrombocytopenia in the real world in patients with mCPRC.

Initiation of treatment with PARPi

The voting group strongly agreed with the recommendation to perform a full biological assessment before starting PARPi treatment, including blood count, serum creatinine, iron status and vitamin B9 (folate) concentration. Haematological disorders, in particular anaemia, are common in prostate cancer patients and may have different aetiologies, either linked to the patient’s general condition and cancer (iron deficiency, bone marrow invasion, etc.) or treatment (androgenic deprivation, systemic chemotherapy, etc.).^30,31 A low haemoglobin level on PARPi initiation is associated with increased risk of grade ⩾3 anaemia, neutropenia or thrombocytopenia once on PARPi.³² These haematological disorders should therefore be investigated before PARPi initiation so that appropriate corrective measures can be implemented.

Several statements offering guidance for specific patients were validated. The statement that pre-existing anaemia should not delay PARPi initiation, provided corrective measures and close monitoring are implemented, achieved a GOOD consensus, probably due to the proposed threshold of a haemoglobin level ⩾10 g/dl. Indeed, in some clinical studies, a level of 9 g/dl has been recommended.^14,15 However, given real-life experience and general patient status (older, frailer and often anaemic), a threshold of ideally 10 g/dl was felt to be more clinically appropriate to initiate PARPi treatment under optimal conditions and limit subsequent dose interruptions or reductions.

Similarly, it was agreed that a delay must be observed before initiating PARPi after the last course of chemotherapy to allow sufficient time for haematological recovery. Selle et al.²³ have proposed a 6–8-week delay based on the results from studies in ovarian cancer patients treated with platinum-based chemotherapy. However, in the mCRPC clinical trials, a 3- or 4-week delay was allowed between the two treatments. Considering this and practical experience, the experts strongly agreed on the need to observe a minimum delay of 4 weeks.

Although the median age at mCRPC diagnosis is 72 years,³³ no statement specific to elderly patients was submitted to the experts. This fits with Selle et al.²³ who previously recommended not reducing the PARPi dose in elderly or frail patients without good pharmacological reason (significant haematological toxicity on previous chemotherapy or increased exposure to PARPi due to renal or hepatic impairment or drug interactions); advising patients to be vigilant for certain symptoms (malnutrition, gastrointestinal, sensory, balance, cognitive disorders, hyper- or hypotension); and organising a pre-therapeutic onco-geriatric consultation in the event of a geriatric syndrome, progressive co-morbidities or any doubt about the patient’s ability to take their treatment completely independently. In addition, pharmacokinetic studies have not found any impact of age on PARPi exposure, therefore PARPi SmPCs do not recommend any dose adjustment for the elderly population.^13
–16,34

Haematological monitoring

As it is recognised that the onset of haematological toxicities induced by PARPi is more marked in the first few weeks,³⁵ there was STRONG consensus to monitor this frequently during the first few months of treatment. However, significant differences in onset have been reported between PARPi, with a median time to onset of 21, 23, 36 and 63 days, across all organs, for niraparib, rucaparib, talazoparib and olaparib, respectively.³⁵

The voters strongly agreed that this monitoring should be more frequent in profiles at high-risk of toxicity: patients with anaemia following chemotherapy or radiotherapy; with heart, liver or kidney failure and the elderly and/or frail.

Management of haematological toxicities

The 27 statements proposed for the management of grades 2 and 3 anaemia, neutropenia and thrombocytopenia all achieved STRONG consensus, providing precise guidance for assessment and implementation measures; this supplements existing recommendations and SmPCs which are not always detailed.^23
–25 For example, SmPCs do not provide specific guidance for grade 2 anaemia, which is not surprising as, in MAGNITUDE and TALAPRO-2 trials, a haemoglobin level of 9 g/dl was permitted at initiation.^13
–15

Voters agreed that symptomatic grade 2 anaemia – with symptoms including fatigue, weakness, pale skin, chest pain, fast heartbeat or shortness of breath, headache, dizziness, light-headedness, cold hands and feet and loss of appetite – should necessitate holding of PARPi therapy.²⁴ Furthermore, whether for grade 2 or 3 anaemia, neutropenia or thrombocytopenia, voters recommended waiting, ideally for a return to grade 1 before restarting treatment. Indeed, although less restrictive thresholds might be stipulated in trials, patients in the real world are often less fit, so a more conservative threshold may be more appropriate. However, clinicians should adapt the strategy according to the depth of toxicity, taking into account thresholds, the symptomatic nature of the disease and the general condition of patients.

Finally, the experts confirmed that patients with grade 3 anaemia (haemoglobin <8 g/dl) should receive blood transfusions, as well as those with grade 2 anaemia, depending on the intensity of symptoms, speed of onset, comorbidities, particularly cardiac, and any deficiencies needing correction. Although the ESMO guidelines on anaemia management in patients with cancer, and a recent study by Carson et al., suggest that a more restrictive transfusion threshold (7.0–8.0 g/dl) could be adopted, as patients with prostate cancer are often elderly and frail with cardiovascular toxicities, the group based its decision on the French recommendations, which are more in line with their clinical practice.^25,36
–39

Risk of MDS and AML

There was STRONG consensus for confirming situations in which haematological expertise should be sought and a myelogram performed to rule out or confirm MDS/AML: persistent cytopenia beyond 4 weeks despite therapeutic adjustment or holding of PARPi therapy, or a change in the haemogram despite maintenance of an optimal therapeutic dose over the long term. However, the incidence of MDS/AML was ⩽2 cases per study in prostate cancer clinical trials, and estimated to be 0.73% (95% CI: 0.50–1.07) in a meta-analysis.^7
–9,40 The risk of developing MDS/AML with PARPi therefore remains low but should be monitored, according to real-world data, particularly in prostate cancer. A number of risk factors have been identified, including previous treatments such as platinum-based chemotherapy (in ovarian cancers) or radiotherapy, and the presence of somatic or germline genetic abnormalities at tumour level.^13
–15

Clinical implications

Recommendations have been published regarding PARPi management in other cancers, particularly gynaecological.^23,41 While they provide relevant guidelines, they remain more general, addressing adverse effects in a broad sense. The management of haematological toxicities is not always detailed, particularly regarding prevention. In this work, we propose specific guidance on how to manage pre-existing anaemia and specific populations (elderly and/or frail patients, post-CT or radiotherapy anaemia, heart/liver/kidney failure), and prophylaxis. We also provide more detailed guidelines on the practical management of symptomatic low-grade anaemia and neutropenia, nutritional deficiencies and the place of supportive treatments such as EPO.

Limitations

These Delphi recommendations are based on French experience; therefore, the generalisability of the recommendations to other countries with different healthcare systems, patient populations and clinical practices must be considered.

Whilst the aim of this work was to propose detailed, standardised recommendations for PARPi, there are differences between the available PARPi, for example, in terms of monitoring, which is arbitrary and not necessarily based on clinical studies. In addition, in the absence of data, some of the proposals are based on the clinical experience and opinion of the SC and voters. Although the SC and voters are all experienced (median 11 years) in the management of prostate cancer and/or the follow-up of patients with mCRPC or breast/ovarian cancer on PARPi (5 and 10/year, respectively), and 89% of them have participated in research projects or clinical trials with PARPi over the last 5 years, the reliance on expert opinion, while highly valuable, inevitably introduces a degree of subjectivity.

Conclusion

PARPi represent a major advance in mCRPC management. However, haematological toxicities can affect patient exposure to treatment and so limit their effectiveness. Using a Delphi methodology, 38 practical recommendations on the prevention and management of grade 2 and 3 anaemia, neutropenia and thrombocytopenia associated with PARPi in mCRPC patients have been validated by a group of French experts. These proposals complement existing recommendations to guide HCPs in real-life clinical practice and so optimise treatment with PARPi.

Footnotes

Acknowledgements

The authors would like to thank the 33 French healthcare professionals who participated in the two rounds of voting and whose contribution was essential.

Declarations

ORCID iDs

Antonin Schmitt

Florence Joly

References

Ferlay

Ervik

Lam

, et al. Global cancer observatory: cancer today (version 1.1). Lyon, France: International Agency for Research on Cancer, https://gco.iarc.fr/today/ (2024, accessed 10 April 2025).

Congregado

Rivero

Osmán

, et al. PARP inhibitors: a new horizon for patients with prostate cancer. Biomedicines 2022; 10: 1416.

Ploussard

Roubaud

Barret

, et al. French AFU cancer committee guidelines – update 2022–2024: prostate cancer – management of metastatic disease and castration resistance. Prog Urol 2022; 32: 1373–1419.

Oudard

Timsit

M-O

Maillet

, et al. [Metastatic castration-resistant prostate cancer and PARP inhibitors: from tumor genomics to new therapeutic combinations]. Bull Cancer 2025; 112: 61–81.

Rao

Moka

Hamstra

, et al. Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer-where are we now? Cancers (Basel) 2022; 14: 801.

Mateo

Lord

Serra

, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 2019; 30: 1437–1447.

Chi

Rathkopf

Smith

, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol 2023; 41: 3339–3351.

Agarwal

Azad

Carles

, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 2023; 402: 291–303.

Saad

Clarke

Oya

, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24: 1094–1108.

10.

Sayyid

Klaassen

Berlin

, et al. Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis. BJU Int 2023; 132: 619–630.

11.

Bryce

Piulats

Reaume

, et al. Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy. J Clin Oncol 2023; 41: 18–18.

12.

Hussain

Mateo

Fizazi

, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 2020; 383: 2345–2357.

13.

EMA. LYNPARZA (olaparib)-SmPC, https://www.ema.europa.eu/fr/documents/product-information/lynparza-epar-product-information_fr.pdf (2024, accessed 8 September 2025).

14.

EMA. AKEEGA (niraparib/acétate d’abiratérone)-SmPC, https://www.ema.europa.eu/fr/documents/product-information/akeega-epar-product-information_fr.pdf (2024, accessed 8 September 2025).

15.

EMA. TALZENNA (talazoparib)-SmPC, https://www.ema.europa.eu/fr/documents/product-information/talzenna-epar-product-information_fr.pdf (2025, accessed 8 September 2025).

16.

FDA. RUBRACA (Rucaparib)-SmPC, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf (2020, accessed 8 September 2025).

17.

Audeh

Carmichael

Penson

, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245–251.

18.

Mateo

Porta

Bianchini

, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020; 21: 162–174.

19.

Azad

Lincha

Hadigol

, et al. 1834P Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial. Ann Oncol 2023; 34: S992–S993.

20.

Wang

Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials. J Clin Pharm Ther 2021; 46: 571–584.

21.

Zhou

Feng

Zhang

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2017; 11: 3009–3017.

22.

Bowling

Swargaloganathan

Heintz

, et al. Hematological toxicities with PARP inhibitors in prostate cancer: a systematic review and meta-analysis of phase II/III randomized controlled trials. Cancers (Basel) 2023; 15: 4904.

23.

Selle

Boffa

J-J

Etienne

, et al. [Practical management of PARP inhibitors: a French DELPHI consensus]. Bull Cancer 2022; 109: 1245–1261.

24.

Shore

Broder

Barata

, et al. Expert consensus recommendations on the management of treatment-emergent adverse events among men with prostate cancer taking poly-ADP ribose polymerase inhibitor + novel hormonal therapy combination therapy. Eur Urol Oncol 2025; 8: 94–104.

25.

The French National Cancer Institute. Inhibiteurs de PARP: olaparib, niraparib, rucaparib, talazoparib, https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Inhibiteurs-de-PARP-olaparib-niraparib-rucaparib-talazoparib (2022, accessed 23 April 2024).

26.

Hasson

Keeney

McKenna

Research guidelines for the Delphi survey technique. J Adv Nurs 2000; 32: 1008–1015.

27.

HAS. Élaboration de recommandations de bonne pratique-Méthode «Recommandations par consensus formalisé», https://www.has-sante.fr/upload/docs/application/pdf/2011-01/guide_methodologique_consensus_formalise.pdf (2015, accessed 27 June 2024).

28.

Loblaw

Prestrud

Somerfield

, et al. American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol 2012; 30: 3136–3140.

29.

Shang

Use of Delphi in health sciences research: a narrative review. Medicine 2023; 102: e32829.

30.

Shaw

Nielson

Park

, et al. The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. Eur J Haematol 2021; 106: 662–672.

31.

Nalesnik

Mysliwiec

Canby-Hagino

Anemia in men with advanced prostate cancer: incidence, etiology, and treatment. Rev Urol 2004; 6: 1–4.

32.

Azad

Wang

Hadigol

, et al. 1829P Exposure-safety analyses of talazoparib in combination of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2 trial. Ann Oncol 2023; 34: S990.

33.

Barata

Leith

Ribbands

, et al. Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer: results from an international study. Oncologist 2023; 28: e737–e747.

34.

Bruin

MAC

Sonke

Beijnen

, et al. Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology. Clin Pharmacokinet 2022; 61: 1649–1675.

35.

Shu

Ding

, et al. Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database. Cancer Med 2023; 12: 3365–3375.

36.

Aapro

Beguin

Bokemeyer

, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29: iv96–iv110.

37.

Carson

Stanworth

Dennis

, et al. Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev 2021; 12: CD002042.

38.

AFSOS. Anémie et cancer, https://www.afsos.org/wp-content/uploads/2018/01/An%C3%A9mie-et-cancer_AFSOS_2021.pdf (2021, accessed 8 September 2025).

39.

Pathak

Papadopoulos

Kumar

, et al. Frailty in older adults with prostate cancer. Eur Urol Oncol 2025; 8: 14–20.

40.

Morice

P-M

Leary

Dolladille

, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol 2021; 8: e122–e134.

41.

Friedlander

Lee

Tew

WP.

Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data. Am Soc Clin Oncol Educ Book 2023; 43: e390876.

Prevention and management of PARP inhibitor-related haematological toxicities in prostate cancer: French expert opinion using the Delphi method

Abstract

Background:

Objective:

Design:

Methods:

Results:

Conclusion:

Keywords

Introduction

Methodology

Results

Characteristics of respondents

Statements

Discussion

Initiation of treatment with PARPi

Haematological monitoring

Management of haematological toxicities

Risk of MDS and AML

Clinical implications

Limitations

Conclusion

Footnotes

Acknowledgements

Declarations

ORCID iDs

References